Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$8.86MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Yujiro S. Hata
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 145
- Beta
- -0.09
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 18.57
Financials
Revenue
$8.86M-1.2%Net Income
$-112.45MEBITDA
$-121.17MFree Cash Flow
$-89.08MEPS (diluted)
$-1.22Shares Outstanding (diluted)
92.06M+546.5%Operating Expenses
$131.15MCash & Debt
$828.96MReturn of Capital
$0.00Revenue by Segment (annual)
$161.85MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $218.71M | $-113.70M | $-1.28 |
| 2024 | $7.00M | $-274.48M | $-3.36 |
| 2023 | $23.39M | $-112.96M | $-1.96 |
| 2022 | $50.93M | $-58.66M | $-1.42 |
| 2021 | $27.94M | $-49.76M | $-1.41 |
| 2020 | $19.54M | $-34.49M | $-1.31 |
| 2019 | $0.00 | $-41.98M | $-1.90 |
| 2018 | $0.00 | $-34.35M | $-2.41 |
| 2017 | $0.00 | $-11.86M | $-0.83 |
Valuation
IDYAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsprnewswire.com·8d ago·Neutral
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsprnewswire.com·35d ago·Neutral
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
View source ↗ - Newsseekingalpha.com·42d ago·Negative
…. Darovasertib's phase 2 trial showed a median PFS of 6.9 vs. 3.1 months, supporting NDA submission and U.S. commercialization prospects. With $1.24 billion in cash, IDYA can fund operations into 2030, enabling the advancement of multiple proprietary combination franchises.
View source ↗ - Newsprnewswire.com·48d ago·Neutral
… clinical trial, and there will be joint governance to oversee the study SOUTH SAN FRANCISCO, Calif., Aug. 19, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibi…
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-1.17 per share
Typical surprise -3.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-1.22 vs $-1.06miss
- Tue, May 5$-1.11 vs $-1.07miss
- Tue, Feb 17$-0.94 vs $-0.95beat
- Tue, Nov 4$1.33 vs $-0.95beat
- Tue, Aug 5$-0.88 vs $-0.85miss
- Tue, May 6$-0.82 vs $-0.75miss
Estimates and results for IDYA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IDYA officers and directors.
- Bought
- $1.6m
- Sold
- $19.6m
1 trade
21 trades
- Ruiz Briseno Andressold
- Stein Jeffreybought
- White Michael Anthonysold
- White Michael Anthonysold
- Hata Yujiro Ssold
- Hata Yujiro Ssold
- Hata Yujiro Ssold
- Hata Yujiro Ssold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IDYA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.